Apr 28, 2022 / 01:30PM GMT
Mayank Mamtani - B. Riley Securities, Inc. - Analyst
Good morning. Welcome back, everyone, to day two of B. Riley Neuro and Ophthalmology Conference. We thank you all for being part of our conference. And it's my great pleasure to introduce our next presenting company, EyePoint Pharmaceuticals.
Here with me, Jay Duker, the Chief Operating Officer. Thanks, Jay, for being part of this event. Maybe we can kick off our discussion by you giving us an overview of EyePoint.
Obviously, a big transformational year for you guys in the past 12 to 18 months. Would maybe love to hear about the platform that got this going. And then also to see the excitement around the wet AMD program, which we can dive deeper.
Jay Duker - EyePoint Pharmaceuticals, Inc. - COO
Sure. Well, thank you very much for the kind invitation. So EyePoint actually has been a publicly traded company for over 20 years. And its initial product was based on the current sustained-release technology that we call Durasert. It was an implant for CMV retinitis in HIV positive patients. And,
EyePoint Pharmaceuticals Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
Apr 28, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers